Simcere Pharmaceutical Group Limited (HK:2096) has released an update.
Simcere Pharmaceutical Group Limited announced positive results from their phase III clinical trial of ENZESHU for treating platinum-resistant ovarian cancer at the ASCO Annual Meeting. The trial data revealed significant extension of progression-free survival when ENZESHU was combined with chemotherapy, showing promise for patients who had previous treatments with VEGF and/or PARP inhibitors. While overall survival data remains immature, early trends suggest potential benefits, alongside a good safety profile for the treatment.
For further insights into HK:2096 stock, check out TipRanks’ Stock Analysis page.
